124 results
Page 4 of 7
6-K
EX-99.1
umxlu
15 Jun 21
VBL Therapeutics Provides Update on OVAL, a Phase 3 Registration Enabling Study of VB-111 in Ovarian Cancer
7:51am
6-K
EX-99.1
btzbcr8 ig7t8te
4 Jun 21
Current report (foreign)
8:05am
6-K
16og0
11 May 21
Current report (foreign)
7:00am
POS AM
k2shla2rxna k53baa
19 Apr 21
Prospectus update (post-effective amendment)
5:17pm
424B8
gzcg7f5 7lhl
19 Apr 21
Prospectus unintentially filed late
5:06pm
6-K
EX-99.1
bf38excz a4
12 Apr 21
Vascular Biogenics Ltd. Prices Public Offering of Ordinary Shares and Pre-Funded Warrants
9:10am
6-K
EX-1.1
pxbtbmwszf
12 Apr 21
Vascular Biogenics Ltd. Prices Public Offering of Ordinary Shares and Pre-Funded Warrants
9:10am
424B5
yeyma6 t1xap
12 Apr 21
Prospectus supplement for primary offering
9:07am
424B5
t7u 2ptt9m7d9mog56
9 Apr 21
Prospectus supplement for primary offering
12:00am
6-K
EX-99.1
ygvzewe5v
6 Apr 21
VBL Therapeutics Reports Fourth Quarter and Full Year 2020 Financial Results and Provides Corporate Update
3:33pm
6-K
EX-99.3
xnfk4z
15 Jan 21
Ordinary Share Purchase Agreement
7:01am
424B5
yqhrpalmp
15 Jan 21
Prospectus supplement for primary offering
7:00am
F-3
ujksuubjhr7q4ee
30 Dec 20
Shelf registration (foreign)
4:17pm
424B3
zr2gha
16 Nov 20
Prospectus supplement
7:15am
6-K
0omzgv9dg1 e32kayo
16 Nov 20
Current report (foreign)
7:00am
6-K
EX-99.1
kmaa7ae
13 Oct 20
VBL Therapeutics Announces Appointment of Marc Kozin as Vice Chairman of Board of Directors
8:30am
424B3
14693wzpjs22tzgoz11
26 Aug 20
Prospectus supplement
5:21pm
6-K
3lda3by21
13 Aug 20
Current report (foreign)
7:00am
6-K
EX-99.1
nlmrs0fqr5m2hvtn
12 Aug 20
Current report (foreign)
8:45am